BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 18756967)

  • 1. [Clinical significance of pathological response in the breast cancer after neoadjuvant chemotherapy].
    Hui R; Zhang J; Fan Y
    Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(14):961-4. PubMed ID: 18756967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
    Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
    Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
    Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
    Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy.
    Jeruss JS; Mittendorf EA; Tucker SL; Gonzalez-Angulo AM; Buchholz TA; Sahin AA; Cormier JN; Buzdar AU; Hortobagyi GN; Hunt KK
    J Clin Oncol; 2008 Jan; 26(2):246-52. PubMed ID: 18056680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on prognosis in breast cancer patients with extensive axillary disease.
    Hoehne F; Chen S; Mabry H; Giuliano AE
    Breast J; 2008; 14(1):76-80. PubMed ID: 18086270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy.
    Hennessy BT; Hortobagyi GN; Rouzier R; Kuerer H; Sneige N; Buzdar AU; Kau SW; Fornage B; Sahin A; Broglio K; Singletary SE; Valero V
    J Clin Oncol; 2005 Dec; 23(36):9304-11. PubMed ID: 16361629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings.
    Alvarado-Cabrero I; Alderete-Vázquez G; Quintal-Ramírez M; Patiño M; Ruíz E
    Ann Diagn Pathol; 2009 Jun; 13(3):151-7. PubMed ID: 19433292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of neoadjuvant chemotherapy on estrogen and progesterone receptors and P53 and CerbB-2 in breast cancer].
    Bao G; Yang DQ; Zhou B; Liu P; Wang S; Cheng L
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(40):2843-5. PubMed ID: 18167290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Correlation of clinical effect, pathological response of tumor cells and the end results of combined treatment of locally advanced breast cancer].
    Kharchenko VP; Voznyĭ EK; Galil-Ogly GA; Gurov SN; Dobrovol'skaia NI; Alinchenko LA; Bol'shakova SA
    Vopr Onkol; 2000; 46(6):740-4. PubMed ID: 11219951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative clinical, mammographic and sonographic assessment of neoadjuvant chemotherapy response in breast cancer.
    Sperber F; Weinstein Y; Sarid D; Ben Yosef R; Shalmon A; Yaal-Hahoshen N
    Isr Med Assoc J; 2006 May; 8(5):342-6. PubMed ID: 16805235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma?
    Sullivan PS; Apple SK
    Breast J; 2009; 15(2):146-54. PubMed ID: 19292800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose variation and regimen modification of adjuvant chemotherapy in daily practice affect survival of stage I-II and operable stage III Taiwanese breast cancer patients.
    Kuo SH; Lien HC; You SL; Lu YS; Lin CH; Chen TZ; Huang CS
    Breast; 2008 Dec; 17(6):646-53. PubMed ID: 18595699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial.
    Pierga JY; Bidard FC; Mathiot C; Brain E; Delaloge S; Giachetti S; de Cremoux P; Salmon R; Vincent-Salomon A; Marty M
    Clin Cancer Res; 2008 Nov; 14(21):7004-10. PubMed ID: 18980996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Good response to paclitaxel predicts high rates of pathologic complete response for breast cancer patients treated preoperatively with paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide.
    Kim SJ; Taguchi T; Shimazu K; Tanji Y; Tamaki Y; Noguchi S
    Oncology; 2009; 77(2):134-9. PubMed ID: 19628951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant extension of chemotherapy after neoadjuvant therapy may not improve outcome in early-stage breast cancer.
    Knauer M; Haid A; Schneider Y; Köberle-Wührer R; Lang A; Winder T; Alton R; Jasarevic Z; Säly C; Offner FA; Wenzl E; deVries A
    Eur J Surg Oncol; 2009 Aug; 35(8):798-804. PubMed ID: 19013747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of clinical response after two cycles of primary chemotherapy in breast cancer.
    Beresford MJ; Stott D; Makris A
    Breast Cancer Res Treat; 2008 May; 109(2):337-42. PubMed ID: 17624608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of initial clinical disease stage after achieving pathological complete response.
    Dawood S; Broglio K; Kau SW; Islam R; Symmans WF; Buchholz TA; McGuire SE; Meric-Bernstam F; Cristofanilli M; Hortobágyi GN; Gonzalez-Angulo AM
    Oncologist; 2008 Jan; 13(1):6-15. PubMed ID: 18245008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy with vinorelbine-containing regimens in elderly patients with locally advanced breast cancer.
    Ma CD; Chen CM; Chen XS; Liu GY; Di GH; Wu J; Lu JS; Yang WT; Chen JY; Shao ZM; Shen ZZ; Shen KW
    Anticancer Res; 2008; 28(5B):3093-7. PubMed ID: 19031963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.